YERVOY® (IPILIMUMAB) PRESCRIBER ORDER FORM						
Fax	c completed form, insurance in	formation, and	clinical documentatio	on to:		
	Patient Name:		Date of Birth:			
option care health	Address:					
option care nearth	Phone:		Height:	☐ inches ☐ c	cm Weight:	☐ lbs ☐ kg
Clinical Information						
Primary Diagnosis De	escription:		ICD-10 Code:			
Yervoy® (Ipilimumab) Infuse 3 mg/kg IV over 90 minutes once every 3 weeks x 4 doses. Infuse 10 mg/kg IV over 90 minutes once every 3 weeks x 4 doses, then once every 12 weeks. Other: Dispense quantity sufficient of Yervoy® 50 mg and/or 200 mg single dose vials for each dose. Dose will be rounded to closest 50 mg.						
Ancillary Orders						
Pre-Medication Orders Acetaminophen 650 mg PO 30 min before infusion. Patient may decline. Diphenhydramine 25 mg PO 30 min before infusion. Patient may decline. Other: IV Flush Orders Peripheral: Implanted Port: NS 2 to 3 mL pre-/post-use. Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. Lab Orders No labs ordered at this time. Other: Skilled nurse to assess and administer and/or teach self-administration where appropriate via access device as indicated above. Nurse will provide ongoing support as needed. Refill above ancillary orders as directed x 1 year.						
6. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0.	Tappa and the second second distriction di					
I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.						
Prescriber Signature:		Date:				
Prescriber Information						
Prescriber Name:			Phone:		Fax:	
Address:			NPI:			
City, State: Zip:		Office Contact:				

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.